2021
Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents.
Spees L, Dinan M, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Wheeler S. Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents. Journal Of Clinical Oncology 2021, 39: 116-116. DOI: 10.1200/jco.2020.39.28_suppl.116.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anti-cancer agentsPatients' clinical characteristicsProvider-level factorsCause mortalityRenal cell carcinomaClinical characteristicsHazard ratioMetastatic diagnosisCell carcinomaState cancer registry dataCox proportional hazards modelProvider-level predictorsLower overall survivalOral anticancer agentsCancer registry dataReal-world populationProportional hazards modelSkilled nursing facilitiesProvider Enumeration SystemAnti-cancer agentsIndex dateOverall survivalPatient demographicsBlack patients
2020
Predicting prostate cancer death among 98,994 veterans: Differences by race/ethnicity.
Janet T, Danciu I, Justice A, Leapman M, McMahon B, Wadia R. Predicting prostate cancer death among 98,994 veterans: Differences by race/ethnicity. Journal Of Clinical Oncology 2020, 38: e17609-e17609. DOI: 10.1200/jco.2020.38.15_suppl.e17609.Peer-Reviewed Original ResearchProstate cancer deathNon-Hispanic blacksNon-Hispanic whitesVeterans Affairs Healthcare SystemRace/ethnicityHazard ratioGleason scoreCancer deathProstate cancerU.S. Veterans Affairs healthcare systemProstate cancer disease progressionDistant metastatic diseaseProstate cancer mortalityCancer disease progressionLocalized diseasePSA levelsMedian ageMetastatic diseaseLymph nodesPrognostic indexCancer mortalityTumor stageDisease progressionCox modelAge strata
2017
Impact of histologic subtype on bladder cancer outcome.
Washington S, Sanford T, Leapman M, Meng M, Porten S. Impact of histologic subtype on bladder cancer outcome. Journal Of Clinical Oncology 2017, 35: 391-391. DOI: 10.1200/jco.2017.35.6_suppl.391.Peer-Reviewed Original ResearchNational Cancer DatabaseVariant histologySmall cell carcinomaSquamous cell carcinomaBladder cancer outcomesCell carcinomaUrothelial carcinomaHazard ratioOverall survivalIndependent predictorsRadical cystectomyCancer outcomesBlack ethnicityBladder cancerMean age 67 yearsU.S. population-based cohortCommon variant histologyNon-urothelial histologyMultivariable Cox regressionSurgical margin statusAge 67 yearsPathologic T stageWorse overall survivalHistory of chemotherapyPopulation-based cohort